The launch gives Natco an entry in the rapidly growing SGLT-2 segment that has mostly been dominated by global drug makers. However, for roughly a year, the segment has seen the entry of Indian drug maker Glenmark, which launched its versions of remogliflozin at a significantly lower price than MNC brands.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3b13NGs
via IFTTT
0 comments:
Post a Comment